Compare Quest Diagnostics Inc (DGX) vs Essex Property Trust, Inc. (ESS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Essex Property Trust, Inc. — how do they compare? Quest Diagnostics Inc trades at $202.3 (market cap $22.80B), while Essex Property Trust, Inc. trades at $293.32 (market cap $19.16B). The key difference: Quest Diagnostics Inc is the larger of the two by market cap, and Essex Property Trust, Inc. pays the higher dividend (3.47%). Which is the better fit depends on your goals.
| DGX | ESS | |
|---|---|---|
Market Cap | $22.80B | $19.16B |
Sector | Health | Real Estate |
52-Week High | $216.02 | $298.33 |
52-Week Low | $166.42 | $239.61 |
Enterprise Value | $28.82B | $25.88B |
Dividend Yield | 1.67% | 3.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $207.35, showing minimal daily movement with a slight decline of 0.04%. The stock maintains a bullish technical stance with recent earnings beats and analyst consensus pointing to upside potential. Recent developments include New York State approval for Haystack MRD testing and strong momentum across diagnostic channels. Revenue growth accelerated to $11.04 billion in 2025 with consistent profitability margins around 9%.
DGX presents a balanced investment case with 38% analyst buy ratings and a $227.75 price target suggesting 10% upside. The company demonstrates steady revenue growth and operational efficiency, though elevated debt levels and policy risks require monitoring. Second quarter earnings on July 23, 2026, will be crucial for validating current momentum and growth trajectory.
ESS trades at $297.48, up 1.34% today, near its consensus price target of $294.25. The stock shows bullish technical momentum with strong moving average signals and has beaten earnings estimates for three consecutive quarters. Recent news highlights include the upcoming Q2 2026 earnings release and the company's addition to the Russell Microcap Index. Fundamentals remain solid with $1.89B revenue and a 30.03% net income margin in 2025.
Outlook is cautiously optimistic given analyst consensus leaning toward Hold (52.17%) despite recent beats. Key opportunities include AI-driven rental demand in West Coast markets and a sustainable dividend. Risks involve high debt levels (debt-to-asset ratio of 51.92% in 2024) and potential economic sensitivity. The stock offers moderate upside if earnings momentum continues but requires monitoring of leverage and regional market conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Essex Property Trust, Inc.
Essex Property Trust owns a portfolio of 253 apartment communities with over 62,000 units and is developing three additional properties with 571 units. The company focuses on owning large, high-quality properties on the West Coast in the urban and suburban submarkets of Southern California, Northern California, and Seattle.
Read more on ESS →
